ESMO Gastrointestinal Oncology
Publisher: Elsevier · ISSN 2949-8198 · 58 articles
- Early interim CT is the strongest prognostic factor in metastatic gastrointestinal neuroendocrine carcinomas (GI-NEC): results from the French NECTAR study
- Early-onset pancreatic cancer: evidence for a distinct tumor subtype—a systematic review and meta-analysis
- Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆
- Editorial Board
- Table of Contents
- Third-line treatment of biliary tract cancers in a real-life setting
- Prognostic significance of CK7, CK20, and CDX2 expression in small intestinal adenocarcinoma
- Improvement of survival in advanced gastric cancer over 15 years: real-world analysis by 5-year periods
- Adjuvant chemotherapy with or without targeted therapy for patients with resectable synchronous colon cancer and liver or lung-confined metastases: a nationwide Taiwanese database study
- Early-onset biliary tract cancers: clinical and molecular insights
- Reassessing the role of CEA in the treatment of rectal cancer in the era of TNT
- Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands
- The Danish randomized trial of trifluridine–tipiracil and bevacizumab in metastatic colorectal cancer: final survival and post hoc neutropenia and quality-of-life analyses
- Neoadjuvant immunotherapy followed by surgery versus non-operative management in dMMR/MSI gastroesophageal adenocarcinomas: a case series and review of the literature
- Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study
- Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey
- NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study
- The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors
- Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer
- Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer
- Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies
- Structured surveillance in Lynch syndrome: effectiveness, limitations, and unmet needs
- Tumor response to neoadjuvant treatment as a predictor of benefit for adjuvant treatment in esophago-gastric cancers: a systematic review and meta-analysis
- A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma
- Tumor regression grades in locally advanced gastroesophageal adenocarcinoma: associations with survival, pathological risk factors, and molecular biomarkers in a 19-year real-world cohort
- DKN-01 and atezolizumab as second- or third-line therapy in advanced oesophagogastric adenocarcinoma: the WAKING trial
- Age-stratified mutation patterns in early-onset colorectal cancer reveal distinct molecular features and therapeutic implications☆
- Real-world outcomes and prognostic factors of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a multicenter study in Spain
- Adjuvant treatment of gastrointestinal stromal tumors (GIST)—state of the art, controversies, and future directions
- Assessing the relationship between event-free and overall survival in randomized controlled trials of perioperative chemoimmunotherapy in gastroesophageal cancers